Home/Filings/4/0001103021-22-000017
4//SEC Filing

Vollins James 4

Accession 0001103021-22-000017

CIK 0001103021other

Filed

Jan 30, 7:00 PM ET

Accepted

Jan 31, 5:57 PM ET

Size

19.4 KB

Accession

0001103021-22-000017

Insider Transaction Report

Form 4
Period: 2022-01-27
Vollins James
See Remarks
Transactions
  • Exercise/Conversion

    Common Stock

    2022-01-31+8,30324,579 total
  • Exercise/Conversion

    Common Stock

    2022-01-31+3,83428,413 total
  • Exercise/Conversion

    Restricted Stock Units

    2022-01-298,3038,303 total
    Exercise: $0.00Exp: 2023-01-29Common Stock (8,303 underlying)
  • Award

    Restricted Stock Units

    2022-01-27+50,54650,546 total
    Exercise: $0.00Exp: 2025-01-27Common Stock (50,546 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2022-01-313,8340 total
    Exercise: $0.00Exp: 2022-01-31Common Stock (3,834 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2022-01-2716,27632,552 total
    Exercise: $0.00Exp: 2024-01-27Common Stock (16,276 underlying)
  • Award

    Stock Options (right to buy)

    2022-01-27+282,055282,055 total
    Exercise: $3.66Exp: 2032-01-26Common Stock (282,055 underlying)
  • Exercise/Conversion

    Common Stock

    2022-01-27+16,27616,276 total
Footnotes (7)
  • [F1]The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2022.
  • [F2]The stock options were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.
  • [F3]The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.
  • [F4]Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock.
  • [F5]The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 27, 2021, under the Plan. The remaining RSUs vest in equal portions on: (i) January 27, 2023; and (ii) January 27, 2024.
  • [F6]The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 29, 2020, under the Issuer's 2019 Plan. The remaining RSUs vest on January 29, 2023.
  • [F7]The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 31, 2019, under the Issuer's 2011 Equity Incentive Plan, as amended.

Issuer

BIODELIVERY SCIENCES INTERNATIONAL INC

CIK 0001103021

Entity typeother

Related Parties

1
  • filerCIK 0001757833

Filing Metadata

Form type
4
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 5:57 PM ET
Size
19.4 KB